Autres langues Apollomics, Inc.

Actions

APLM

KYG0411D1079

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 27/06/2024			Varia. 5j.	Varia. 1 janv.
0,2082 ^USD	+5,10%		+6,61%	-78,42%

04/06	Apollomics annonce des données sur le Vebreltinib lors de la réunion annuelle 2024 de l'American Society of Clinical Oncology (ASCO)	CI
08/05	Apollomics, Inc. nomme Robert (Bob) Lin au conseil d'administration	CI

Autres langues

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Apollomics Announces Vebreltinib Data at the 2024 American Society of Clinical Oncology Annual Meeting	05/06
Apollomics : BIO 2024 Presentation	04/06
ASCO 2024: Efficacy and safety of the vebreltinib in previously treated, IDH mutant high grade glioma patients with PTPRZ1 MET FUsion GENe (FUGEN): a randomized, multicentre, open label, phase II/III trial	04/06
Apollomics Announces Vebreltinib Data at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting	04/06
Apollomics Announces Vebreltinib Data at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting	04/06
Apollomics Announces Vebreltinib Data At the 2024 American Society of Clinical Oncology Annual Meeting	04/06
Apollomics Announces Presentation at the 2024 BIO International Convention	29/05
Apollomics Announces Presentation at the 2024 BIO International Convention	29/05
Apollomics Announces Private Placement Financing and Addition to Board of Directors	08/05
Apollomics Announces Private Placement Financing and Addition to Board of Directors	08/05
Apollomics, Inc. Appoints Robert Lin to the Board of Directors	08/05
Apollomics, Inc. announced that it has received $5.75 million in funding	08/05
Apollomics, Inc. announced that it expects to receive $5.75 million in funding	06/05
Apollomics : April 2024 Corporate Presentation	25/04
Avistone Biotechnology Co. Ltd. Receives Approval from the National Medical Products Administration of China for Vebrelinib (APL-101) for the Treatment of Gliomas with Met Fusion Gene	25/04
Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion Gene	25/04
Apollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting	10/04
Predicine, Inc. Announces Collaboration with Apollomics, Inc. to Develop Predicinecare as A Companion Diagnostic Assay in Lung Cancer	05/04
Apollomics Announces Poster Presentations of Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting	02/04
Apollomics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Apollomics, Inc.

Actions

APLM

KYG0411D1079

Autres langues

Filtres